After trastuzumab binds to HER2, it induces the receptor-antibody complex to enter the lysosomal degradation pathway through endocytosis, reducing the expression of HER2 on the cell surface and thereby weakening its cancer-promoting activity [32]. This evidence concerns the gene ERBB2 and cancer.